VENTYX BIOSCIENCES INC (VTYX) Stock Price, Quote, News and Overview
NASDAQ:VTYX - Nasdaq - US92332V1070 - Common Stock - Currency: USD
VTYX Quote, Performance and Key Statistics
2.34
-0.11 (-4.49%)
The current stock price of VTYX is 2.34 USD. In the past month the price increased by 29.28%. In the past year, price increased by 1.3%.
VTYX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.36 | 734.92B | ||
| JNJ | JOHNSON & JOHNSON | 15.17 | 366.71B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.57 | 304.42B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.44 | 237.03B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.87 | 216.57B | ||
| MRK | MERCK & CO. INC. | 10.15 | 198.62B | ||
| PFE | PFIZER INC | 7.54 | 137.53B | ||
| SNY | SANOFI-ADR | 10.49 | 116.45B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.31 | 94.33B | ||
| GSK | GSK PLC-SPON ADR | 8.54 | 78.19B | ||
| ZTS | ZOETIS INC | 25.94 | 69.53B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.92 | 47.17B |
Related stock screener links
About VTYX
Company Profile
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in San Diego, California and currently employs 79 full-time employees. The company went IPO on 2021-10-21. The firm is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Company Info
VENTYX BIOSCIENCES INC
12790 El Camino Real, Suite 200
San Diego CALIFORNIA US
Employees: 73
Phone: 18589452393
VENTYX BIOSCIENCES INC / VTYX FAQ
What is the stock price of VENTYX BIOSCIENCES INC today?
The current stock price of VTYX is 2.34 USD. The price decreased by -4.49% in the last trading session.
What is the ticker symbol for VENTYX BIOSCIENCES INC stock?
The exchange symbol of VENTYX BIOSCIENCES INC is VTYX and it is listed on the Nasdaq exchange.
On which exchange is VTYX stock listed?
VTYX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VENTYX BIOSCIENCES INC stock?
15 analysts have analysed VTYX and the average price target is 12.24 USD. This implies a price increase of 423.08% is expected in the next year compared to the current price of 2.34. Check the VENTYX BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VENTYX BIOSCIENCES INC worth?
VENTYX BIOSCIENCES INC (VTYX) has a market capitalization of 166.51M USD. This makes VTYX a Micro Cap stock.
How many employees does VENTYX BIOSCIENCES INC have?
VENTYX BIOSCIENCES INC (VTYX) currently has 73 employees.
What are the support and resistance levels for VENTYX BIOSCIENCES INC (VTYX) stock?
VENTYX BIOSCIENCES INC (VTYX) has a support level at 2.19 and a resistance level at 2.57. Check the full technical report for a detailed analysis of VTYX support and resistance levels.
Should I buy VENTYX BIOSCIENCES INC (VTYX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VTYX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VTYX, evaluating the profitability, health, valuation and growth aspects
- VENTYX BIOSCIENCES INC (VTYX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VENTYX BIOSCIENCES INC (VTYX) Sales and EPS estimates to see what analysts future expectations are.
- VENTYX BIOSCIENCES INC (VTYX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VENTYX BIOSCIENCES INC (VTYX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VENTYX BIOSCIENCES INC (VTYX) Stock Chart to make your own analysis
- VENTYX BIOSCIENCES INC (VTYX) Latest news and press-releases to stay up to date.
Does VENTYX BIOSCIENCES INC (VTYX) stock pay dividends?
VTYX does not pay a dividend.
What is the Price/Earnings (PE) ratio of VENTYX BIOSCIENCES INC (VTYX)?
VENTYX BIOSCIENCES INC (VTYX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.75).
What is the Short Interest ratio of VENTYX BIOSCIENCES INC (VTYX) stock?
The outstanding short interest for VENTYX BIOSCIENCES INC (VTYX) is 9.87% of its float. Check the ownership tab for more information on the VTYX short interest.
VTYX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VTYX. When comparing the yearly performance of all stocks, VTYX is one of the better performing stocks in the market, outperforming 93.3% of all stocks.
VTYX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VTYX. VTYX has a great financial health rating, but its profitability evaluates not so good.
VTYX Financial Highlights
Over the last trailing twelve months VTYX reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS increased by 45.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.92% | ||
| ROE | -53.53% | ||
| Debt/Equity | 0 |
VTYX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to VTYX. The Buy consensus is the average rating of analysts ratings from 15 analysts.